441 related articles for article (PubMed ID: 18850474)
41. [Expression of matrix metalloproteinase-2, -9 and their inhibitor-1 in hypertrophic scars].
Xie XF; He LX; Hao XF; Chen B; Jia CY; Sun ZG; Cao YJ; Li DH
Zhonghua Shao Shang Za Zhi; 2007 Dec; 23(6):444-6. PubMed ID: 18457258
[TBL] [Abstract][Full Text] [Related]
42. [Expression of mRNA of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase after cardiopulmonary resuscitation for asphyxial cardiac arrest in rat].
Li ZP; Chen SQ; Wang SS; Huang WJ; Cheng JY; Wang W; Wang WT; Tan YX
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Sep; 17(9):548-51. PubMed ID: 16146602
[TBL] [Abstract][Full Text] [Related]
43. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study.
Peake NJ; Khawaja K; Myers A; Jones D; Cawston TE; Rowan AD; Foster HE
Rheumatology (Oxford); 2005 Nov; 44(11):1383-9. PubMed ID: 16049050
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
[TBL] [Abstract][Full Text] [Related]
45. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
46. Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) in cerebral cavernous malformations: immunohistochemical analysis of MMP-2, -9 and TIMP-2.
Fujimura M; Watanabe M; Shimizu H; Tominaga T
Acta Neurochir (Wien); 2007 Feb; 149(2):179-83; discussion 183. PubMed ID: 17043747
[TBL] [Abstract][Full Text] [Related]
47. Role of matrix metalloproteinases and their tissue inhibitor of metalloproteinases in myxomatous change of cardiac floppy valves.
Togashi M; Tamura K; Nitta T; Ishizaki M; Sugisaki Y; Fukuda Y
Pathol Int; 2007 May; 57(5):251-9. PubMed ID: 17493172
[TBL] [Abstract][Full Text] [Related]
48. Elevated gene expression of MMP-1, MMP-10, and TIMP-1 reveal changes of molecules involved in turn-over of extracellular matrix in cyclosporine-induced gingival overgrowth.
Dannewitz B; Edrich C; Tomakidi P; Kohl A; Gabbert O; Eickholz P; Steinberg T
Cell Tissue Res; 2006 Sep; 325(3):513-22. PubMed ID: 16670920
[TBL] [Abstract][Full Text] [Related]
49. Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients.
Zdzisińska B; Walter-Croneck A; Kandefer-Szerszeń M
Leuk Res; 2008 Nov; 32(11):1763-9. PubMed ID: 18472160
[TBL] [Abstract][Full Text] [Related]
50. The expression of human corneal MMP-2, MMP-9, proMMP-13 and TIMP-1 in bullous keratopathy and keratoconus.
Predović J; Balog T; Marotti T; Gabrić N; Bohac M; Romac I; Dekaris I
Coll Antropol; 2008 Oct; 32 Suppl 2():15-9. PubMed ID: 19138000
[TBL] [Abstract][Full Text] [Related]
51. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
[TBL] [Abstract][Full Text] [Related]
52. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.
Giannopoulos G; Pavlakis K; Parasi A; Kavatzas N; Tiniakos D; Karakosta A; Tzanakis N; Peros G
Anticancer Res; 2008; 28(3B):1875-81. PubMed ID: 18630474
[TBL] [Abstract][Full Text] [Related]
53. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
Mannello F; Jung K; Tonti GA; Canestrari F
Clin Biochem; 2008 Dec; 41(18):1466-73. PubMed ID: 18926810
[TBL] [Abstract][Full Text] [Related]
54. Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides.
Gattorno M; Vignola S; Falcini F; Sabatini F; Buoncompagni A; Simonini G; Picco P; Pistoia V
J Rheumatol; 2002 Apr; 29(4):826-31. PubMed ID: 11950028
[TBL] [Abstract][Full Text] [Related]
55. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
[TBL] [Abstract][Full Text] [Related]
56. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
57. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
[TBL] [Abstract][Full Text] [Related]
58. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.
Montagnana M; Volpe A; Lippi G; Caramaschi P; Salvagno GL; Biasi D; Bambara LM; Guidi GC
Clin Biochem; 2007 Aug; 40(12):837-42. PubMed ID: 17493602
[TBL] [Abstract][Full Text] [Related]
59. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
González-Cuevas J; Bueno-Topete M; Armendariz-Borunda J
J Gastroenterol Hepatol; 2006 Oct; 21(10):1544-54. PubMed ID: 16928215
[TBL] [Abstract][Full Text] [Related]
60. Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy.
Sampson M; Wall S; Baugh M; Worley J; Davies I; Hughes D; Gavrilovic J
Diabetes Res Clin Pract; 2006 Jan; 71(1):45-51. PubMed ID: 16023759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
